Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.
P & T : a peer-reviewed journal for formulary management(2018)
Abstract
Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia.
MoreTranslated text
Key words
tardive dyskinesia,ingrezza,treatment,fda-approved
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined